Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC

Conditions: Small Cell Lung Cancer Extensive Stage Interventions: Drug: α-PD-L1/4-1BB DLL3 CAR-T (BHP01) Sponsors: Sichuan University; Chengdu Brilliant Pharmaceutical Co., Ltd. Not yet recruiting

https://clinicaltrials.gov/study/NCT06348797

Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials